Takeda Pharmaceutical Co Ltd - Dec 3, 2021 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
10%+ Owner
Signature
/s/ Yoshihiro Nakagawa, Corporate Officer, Global General Counsel of Takeda Pharmaceutical Company Limited
Stock symbol
DAWN
Transactions as of
Dec 3, 2021
Transactions value $
-$1,994,530
Form type
4
Date filed
12/7/2021, 05:01 AM
Previous filing
Nov 29, 2021
Next filing
Dec 9, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Sale -$231K -12.5K -0.19% $18.47 6.52M Dec 3, 2021 See Explanation of Responses F1, F2, F3, F4
transaction DAWN Common Stock Sale -$1.76M -97.7K -1.5% $18.05 6.42M Dec 6, 2021 See Explanation of Responses F2, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $18.10 to $18.78. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.
F2 This statement is being filed jointly by Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A. Inc., Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc.
F3 Takeda Pharmaceutical Company Limiteds beneficial ownership of the reported securities is comprised of 6,360,173 shares of Common Stock held by Millennium Pharmaceuticals, Inc. and 57,224 shares of Common Stock held by Takeda Ventures, Inc. Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc. are each direct, wholly owned subsidiaries of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%).
F4 Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. may be deemed to share voting and dispositive power over the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. disclaims beneficial ownership of the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. except to the extent of their pecuniary interests therein.
F5 Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $18.00 to $18.27. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.